Phase III Clinical Study of JTE-052 new drug product - Bioequivalence study between new drug product and JTE-052 ointment in patients with atopic dermatitis -

Start Date22 Apr 2024

Sponsor / Collaborator-

JPRN-jRCT2031230570

/ CompletedPhase 1IIT

Phase I Clinical Study of JTE-052 new drug product - Dermal Safety Study -

Start Date19 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Delgocitinib

100 Translational Medicine associated with Delgocitinib

100 Patents (Medical) associated with Delgocitinib

110

Literatures (Medical) associated with Delgocitinib

01 Feb 2025·JOURNAL OF DERMATOLOGY

English version of clinical practice guidelines for the management of atopic dermatitis 2024

Article

Author: Nakahara, Takeshi ; Narita, Masami ; Tanizaki, Hideaki ; Furuta, Junichi ; Arakawa, Hirokazu ; Katsunuma, Toshio ; Matsubara, Tomoyo ; Tsunemi, Yuichiro ; Yamamoto‐Hanada, Kiwako ; Murota, Hiroyuki ; Futamura, Masaki ; Saeki, Hidehisa ; Nagao, Mizuho ; Ohya, Yukihiro ; Katoh, Norito ; Ichiyama, Susumu ; Hide, Michihiro ; Tanaka, Akio ; Fujisawa, Takao ; Masuda, Koji

Abstract:

This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti‐inflammatory drugs, such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment, have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate‐to‐severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In these revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity‐related patient outcomes with respect to several important points requiring decision‐making in clinical practice.

01 Jan 2025·CONTACT DERMATITIS

Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI‐75 and HECSI‐90 as within‐patient responder definitions

Article

Author: Agner, Tove ; Grant, Laura ; Lehmann, Lucine ; Thoning, Henrik ; Yüksel, Yasemin Topal ; Larsen, Lotte Seiding ; Arbuckle, Rob

Abstract:

Background:

The Hand Eczema Severity Index (HECSI) is a Clinician‐Reported Outcome measure of the severity of hand eczema (HE).

Objectives:

This study aimed to evaluate the validity, reliability and ability to detect change of the HECSI, and the HECSI‐75 and HECSI‐90 as responder definitions.

Methods:

Analyses were performed using data from a sample of n = 258 patients with Chronic Hand Eczema (CHE) from a Phase 2b, randomised, double‐blind, vehicle‐controlled trial of delgocitinib cream, pooled across treatment groups. The measurement properties of the HECSI were assessed and the adequacy of the HECSI‐75 and HECSI‐90 as responder definitions was explored through cross‐tabulation.

Results:

Inter‐item correlations provided support for the scoring, whereby items are grouped by areas of the hand. HECSI demonstrated good test–retest reliability with intra‐class correlations >0.70. Construct validity was supported by a logical pattern of correlations with concurrent measures and significant differences in HECSI scores across severity groups (p < 0.001). HECSI was responsive with statistically significant improvements over time and with significant differences (p < 0.001) between improved and stable groups. Data provided support for both HECSI‐75 and HECSI‐90 as within‐patient responder definitions.

Conclusions:

HECSI has strong validity, reliability and ability to detect change as a measure of CHE severity. HECSI‐75 and HECSI‐90 are appropriate responder definitions.

01 Dec 2024·CLINICAL AND EXPERIMENTAL ALLERGY

Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis

Review

Author: Doyle, Megan ; Williams, Hywel C. ; Stuart, Beth ; Futamura, Masaki ; Roberts, Amanda ; Axon, Emma ; Parker, Roses ; Santer, Miriam ; Steele, Lloyd ; Boyle, Robert J. ; Cro, Suzie ; Chu, Derek K. ; Lax, Stephanie J. ; Van Vogt, Eleanor ; Reynolds, Clare ; Candy, Bridget ; Drucker, Aaron M.

ABSTRACT:

Objective:

Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain.

Design:

Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments.

Data Sources:

Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.

Eligibility Criteria for Selected Trials:

Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory.

Results:

We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids.

Conclusion:

Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema.

News (Medical) associated with Delgocitinib

04 Feb 2025

·www.businesswire.com

LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)

BALLERUP, Denmark--( BUSINESS WIRE )-- NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results of the DELTA TEEN trial. DELTA TEEN is a pivotal phase 3 clinical trial with Anzupgo ® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of adolescents (aged 12-17) with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. 1 This is the fifth phase 3 Anzupgo trial to achieve primary and all key secondary endpoints, validating the results of the previous clinical trials from the DELTA program. 1,3-10 DELTA TEEN expands LEO Pharma’s growing portfolio of scientific evidence for the treatment of moderate to severe CHE, offering insight into a new patient population. Currently, no treatment options are approved specifically for moderate to severe CHE in the adolescent population. " Research on adolescents with CHE has revealed that the condition can considerably affect their quality of life, including psychosocial well-being, school performance and leisure activities," said Professor Sonja Molin, Academic Dermatologist at Charite Universitätsmedizin Berlin and Adjunct Associate Professor of Dermatology at Queen’s University and coordinating investigator. " These findings further our understanding of how moderate to severe CHE manifests in adolescents and how to support this underserved patient group." The trial met the primary endpoint with a statistically significant improvement in CHE symptoms after 16 weeks of treatment with Anzupgo compared to cream vehicle. 1 Furthermore, the safety profile of Anzupgo was consistent with previous pivotal trials. 1 “ The positive results from DELTA TEEN are encouraging and in line with LEO Pharma’s purpose of serving more and more people living with this debilitating condition,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma . “ Anzupgo is already available to adults in some markets, including Germany, and it is a critical next step to address the unmet need in this younger patient population.” Currently, Anzupgo is approved for adults in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate, and is under investigation in other markets, including the United States. Detailed results from DELTA TEEN are planned to be submitted for scientific presentation and publication at a later date. For more information on the DELTA TEEN trial (NCT05355818) go to clinicaltrials.gov . Notes to editors About Anzupgo ® (delgocitinib) cream Anzupgo is currently approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. Anzupgo is under investigation in other markets, including the United States. Anzupgo ® (delgocitinib) cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE. 11 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome. 12 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. About the DELTA TEEN Trial DELTA TEEN was a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel group, multi-site trial to evaluate the efficacy and safety of twice-daily applications of Anzupgo compared with cream vehicle in adolescents 12-17 years of age with moderate to severe CHE. 1 The primary endpoint of DELTA TEEN was the Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) at Week 16. Treatment success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline. 1 About Chronic Hand Eczema Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year. 13,14 HE is the most common skin disorder of the hands 15 with a prevalence rate of approximately 4.7%. 16 In a substantial number of patients, HE can develop into a chronic condition. 15 CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists. 17 CHE has been shown to cause psychological and functional burdens that impact patient quality of life, 18 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition. 19 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE. 20 About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of EUR 1.5 billion. References ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN). Identifier: NCT05355818. https://clinicaltrials.gov/study/NCT05355818 . Haft MA, Park HH, Lee SS, Sprague JM, Eichenfield LF. Pediatric chronic hand eczema: Epidemiology, clinical presentation, and management. JAAD Int. 2023;11:165-173. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). Identifier: NCT04871711. https://clinicaltrials.gov/ct2/show/NCT04871711 . ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2). Identifier: NCT04872101. https://clinicaltrials.gov/ct2/show/NCT04872101 . ClinicalTrials.gov. National Library of Medicine (U.S.). Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA 3). Identifier: NCT04949841 https://clinicaltrials.gov/ct2/show/NCT04949841 . Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461-473. doi:10.1016/S0140-6736(24)01027-4. Schliemann S, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 DELTA 2 trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023. Berlin, Germany. 11– 14 October. Poster Presentation #P0395. Bissonnette R, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 DELTA 1 trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023. Berlin, Germany. 11– 14 October. Poster Presentation #P0369. ClinicalTrials.gov. National Library of Medicine (U.S.). A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema. Identifier: NCT05259722. https://clinicaltrials.gov/study/NCT05259722 . Giménez-Arnau AM, Pinter A, Sondermann W et al. DELTA FORCE trial: 24-week Phase 3 trial comparing the efficacy and safety of topical delgocitinib cream with oral alitretinoin capsules in adults with severe CHE. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024. Amsterdam, Netherlands. 25-28 September. Late Breaking News Session. D1T01 Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-79328 February 2025

Phase 3License out/inClinical ResultDrug Approval

13 Jan 2025

·pmlive.com

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Gilead Sciences and LEO Pharma have entered into a strategic partnership worth $1.7bn to advance LEO’s small molecule oral STAT6 programme for inflammatory diseases. The deal gives Gilead global rights to develop, manufacture and commercialise the oral STAT6 programme. Meanwhile, LEO will hold exclusive global rights to STAT6 topical formulations in dermatology, and will have the option to co-commercialise oral programmes for dermatology indications outside the US. In exchange, LEO will be eligible for up to $1.7bn, including an upfront payment of $250m and approximately $1.5bn in development, regulatory and commercial milestones. LEO may also receive tiered royalties on sales of oral STAT6 products, while Gilead could be in line for tiered royalties on sales of topical STAT6 products. Flavius Martin, executive vice president, research, Gilead, said the company is “committed to developing next-generation therapies to support long-term remission in patients with inflammatory diseases through mechanisms that block major pathogenic pathways, eliminate pathogenic cells, tolerise the immune system, and restore cell function”. “By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions,” he added. STAT6 is the specific transcription factor used for interleukin-4 and interleukin-13 cytokine signalling, which has been shown to play a key role in multiple inflammatory conditions, including atopic dermatitis, asthma and chronic obstructive pulmonary disease. The approach has already shown potential pre-clinically to treat a broad population of patients and provide an oral alternative to those currently receiving injectable biologics. “STAT6 holds potential for treating various inflammatory diseases, including outside dermatology,” said LEO’s chief executive officer, Christophe Bourdon. “This strategic partnership with Gilead will enable us to accelerate the development of the STAT6 programme and maximise its potential in dermatology and beyond.” The announcement comes just over a month after LEO’s Anzupgo (delgocitinib) cream was approved by the Medicines and Healthcare Products Regulatory Agency to treat chronic hand eczema in adults with moderate-to-severe cases of the inflammatory skin disease. The company is now working with the National Institute for Health and Care Excellence to make the treatment available on the NHS.

Drug ApprovalLicense out/in

05 Dec 2024

·www.pharmaceutical-technology.com

LEO Pharma’s eczema cream gains MHRA marketing authorisation

Anzupgo (delgocitinib) 20mg/g cream is intended to treat moderate to severe chronic hand eczema in adults. Credit: Kmpzzz/Shutterstock. Leo Pharma has gained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib) 20mg/g cream, to treat chronic hand eczema (CHE) in Britain. The approval enables the treatment of adults with moderate to severe CHE when topical corticosteroids are inadequate or inappropriate. The decision was based on the positive outcomes of the Phase III programme, which encompassed the DELTA 1 and DELTA 2 trials. The trials assessed the cream’s efficacy and safety against a cream vehicle, meeting their primary and secondary goals. Subjects from the DELTA 1 and DELTA 2 trials were given the opportunity to join the DELTA 3 trial, a 36-week open-label extension study. LEO Pharma UK and Ireland vice-president and general manager Leanne Walsh stated: “Today’s MHRA approval of delgocitinib cream marks a significant milestone for adults in Great Britain living with moderate to severe chronic hand eczema. “This approval offers a new treatment paradigm and demonstrates our commitment to addressing the unmet needs of people living with skin conditions.” The cream targets the JAK-STAT signalling pathway involved in CHE pathogenesis. The condition is marked by skin barrier dysfunction, inflammation and changes in the skin microbiome. The current approval of delgocitinib cream adds to its existing authorisations in the European Union and Switzerland for the same indication. LEO Pharma obtained exclusive development and commercialisation rights to the cream for dermatological uses globally, excluding Japan, through a license agreement with Japan Tobacco (JT) in 2014. JT holds the rights in Japan. In September 2024, the European Commission (EC) granted marketing authorisation for delgocitinib cream to treat adults with moderate to severe CHE. LEO Pharma UK and Ireland is working with the National Institute for Health and Care Excellence ( Nice ) to ensure the cream’s availability on the National Health Service (NHS). Chronic hand eczema is a complex and variable inflammatory skin condition, with primary symptoms such as itching and pain affecting the hands and wrists.

Phase 3Drug ApprovalLicense out/inClinical Result

100 Deals associated with Delgocitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11046	-	D11AH	DB16133

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic eczema	EU	LEO Pharma A/S	19 Sep 2024
Chronic eczema	IS	LEO Pharma A/S	19 Sep 2024
Chronic eczema	LI	LEO Pharma A/S	19 Sep 2024
Chronic eczema	NO	LEO Pharma A/S	19 Sep 2024
Dermatitis, Atopic	JP	Japan Tobacco, Inc.	23 Jan 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mandibulofacial Dysostosis	Phase 3	CN	Shanghai Leo Pharmaceutical Consulting Co., Ltd.	05 Sep 2023
Mandibulofacial Dysostosis	Phase 3	CN	LEO Pharma A/S	05 Sep 2023
Mandibulofacial Dysostosis	Phase 3	CN	LEO Laboratories Ltd.	05 Sep 2023
Eczema, Dyshidrotic	Phase 3	DK	Japan Tobacco, Inc.	30 Jan 2022
Eczema, Dyshidrotic	Phase 3	DK	LEO Pharma A/S	30 Jan 2022
Frontal Fibrosing Alopecia	Phase 2	DK	Japan Tobacco, Inc.	30 Jan 2022
Lupus Erythematosus, Discoid	Phase 2	US	Leo Pharma, Inc.	09 Jul 2019
Lupus Erythematosus, Discoid	Phase 2	DK	Leo Pharma, Inc.	09 Jul 2019
Lupus Erythematosus, Discoid	Phase 2	FR	Leo Pharma, Inc.	09 Jul 2019
Lupus Erythematosus, Discoid	Phase 2	DE	Leo Pharma, Inc.	09 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04949841 (DELTA 3, CTgov)	Phase 3	Chronic eczema	801	Delgocitinib	olnpiojotr(uuoritcnpd) = bkbdnasujw uiiypbgeyg (jxfehnujjw, qyzutigjki - sbvxynetui) View more	-	20 Jan 2025
NCT05259722 (BusinessWire) Manual	Phase 3	Chronic eczema	513	Delgocitinib cream	olbdwyyzwb(ffkpwkotbn) = yneujepcaw ihkzjxjdic (pycvvpegyh ) Met View more	Positive	25 Sep 2024
				Alitretinoin capsules	olbdwyyzwb(ffkpwkotbn) = qsjzugtsoz ihkzjxjdic (pycvvpegyh ) Met View more
NCT04872101 \| NCT04871711 (DELTA 2, Pubmed) Manual	Phase 3	Eczema	-	Delgocitinib cream 20 mg/g	zgmhflksdb(twggmlfwxo) = vvyzphdqhp ipxvtnogbz (djdxrsnmwy ) View more	Positive	01 Jul 2024
				Cream vehicle	zgmhflksdb(twggmlfwxo) = shugwrnhko ipxvtnogbz (djdxrsnmwy ) View more
NCT04949841 (DELTA 3, BusinessWire) Manual	Phase 3	Chronic eczema	801	Delgocitinib cream	ggtlsajazx(nagdhrqmps) = COVID-19 and nasopharyngitis gxbrdevjsn (zuyiyxldmg )	Positive	10 Mar 2024
NCT04949841 (DELTA 3, NEWS) Manual	Phase 3	Eczema, Dyshidrotic	-	delgocitinib	ssyqiozkhl(syvldcwnvg) = safety profile of twice-daily treatment with delgocitinib cream for up to 36 weeks was consistent with previous results from DELTA 1 and 2. caklkxqfih (ksbfvekmlc ) View more	Positive	31 Oct 2023
NCT04872101 (DELTA 2, NEWS) Manual	Phase 3	Eczema, Dyshidrotic	473	Delgocitinib	augynteanz(lvjoaebjfq) = ofcjsheibk ssahfdqnhm (shlhtmzawt ) View more	Positive	13 Oct 2023
				cream vehicle	augynteanz(lvjoaebjfq) = seermklujo ssahfdqnhm (shlhtmzawt ) View more
NCT04872101 \| NCT04871711 (DELTA 1 and DELTA 2, EADV2023)	Phase 3	Chronic eczema	639	Delgocitinib cream 20 mg/g	bzffmnikyd(hlcttiewwr): difference = 0.11 (95% CI, 0.08 - 0.13)	Positive	11 Oct 2023
				Cream vehicle
NCT04872101 (DELTA 2, EADV2023)	Phase 3	Eczema, Dyshidrotic	-	Delgocitinib cream 20 mg/g	uqkkxdejzw(ojigajhshq) = chgsjmlazm kszedbogxk (uuzixamnic )	-	11 Oct 2023
NCT04872101 (DELTA 2, EADV2023)	Phase 3	Eczema, Dyshidrotic	-	Delgocitinib cream 20 mg/g	xflahmmimx(ttefjbryng) = izgqqtqjma jcrbgscgnb (jbxpinjgkf ) View more	Positive	11 Oct 2023
				Cream vehicle	xflahmmimx(ttefjbryng) = hieqgjtqhf jcrbgscgnb (jbxpinjgkf ) View more
NCT04871711 (DELTA 1, EADV2023)	Phase 3	Eczema, Dyshidrotic	487	Delgocitinib cream 20 mg/g	gjmdaxnbtt(erlhtegwxn) = pwruhllbpt lricuwfzmw (emmzsygbzy ) View more	Positive	11 Oct 2023
				Cream vehicle	gjmdaxnbtt(erlhtegwxn) = ooucfbpuwd lricuwfzmw (emmzsygbzy ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Delgocitinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation